The Consequences of GBA Deficiency in the Autophagy–Lysosome System in Parkinson’s Disease Associated with GBA
暂无分享,去创建一个
[1] M. Vila,et al. Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology , 2022, npj Parkinson's Disease.
[2] A. Schapira,et al. Glucocerebrosidase mutations and Parkinson disease , 2022, Journal of Neural Transmission.
[3] T. Noma,et al. Redefining GBA gene structure unveils the ability of Cap-independent, IRES-dependent gene regulation , 2022, Communications Biology.
[4] R. Krüger,et al. GBA-associated PD: chances and obstacles for targeted treatment strategies , 2022, Journal of Neural Transmission.
[5] A. Schapira,et al. GBA Variants and Parkinson Disease: Mechanisms and Treatments , 2022, Cells.
[6] Ori J. Lieberman,et al. Mutant glucocerebrosidase impairs α-synuclein degradation by blockade of chaperone-mediated autophagy. , 2022, Science advances.
[7] N. Engedal,et al. Measuring Autophagic Cargo Flux with Keima-Based Probes. , 2022, Methods in molecular biology.
[8] R. Pellegrino,et al. Drug-Induced Lysosomal Impairment Is Associated with the Release of Extracellular Vesicles Carrying Autophagy Markers , 2021, International journal of molecular sciences.
[9] B. Nordén,et al. Orientation of α-Synuclein at Negatively Charged Lipid Vesicles: Linear Dichroism Reveals Time-Dependent Changes in Helix Binding Mode , 2021, Journal of the American Chemical Society.
[10] A. Cuervo,et al. Autophagy and the hallmarks of aging , 2021, Ageing Research Reviews.
[11] D. Wesson,et al. Heterozygous GBA D409V and ATP13a2 mutations do not exacerbate pathological α-synuclein spread in the prodromal preformed fibrils model in young mice , 2021, Neurobiology of Disease.
[12] K. Setchell,et al. Substrate Reduction Therapy Reverses Mitochondrial, mTOR, and Autophagy Alterations in a Cell Model of Gaucher Disease , 2021, Cells.
[13] A. Ballabio,et al. Autophagy in major human diseases , 2021, The EMBO journal.
[14] E. Gazit,et al. Glucosylceramide Associated with Gaucher Disease Forms Amyloid-like Twisted Ribbon Fibrils That Induce α-Synuclein Aggregation , 2021, ACS nano.
[15] T. Lamark,et al. Mechanisms of Selective Autophagy. , 2021, Annual review of cell and developmental biology.
[16] Monika Kandebo,et al. Decreased glucocerebrosidase activity and substrate accumulation of glycosphingolipids in a novel GBA1 D409V knock-in mouse model , 2021, PloS one.
[17] N. Krogan,et al. Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome , 2021, Cell.
[18] Elias T. Zambidis,et al. Elevated glucosylsphingosine in Gaucher disease induced pluripotent stem cell neurons deregulates lysosomal compartment through mammalian target of rapamycin complex 1 , 2021, Stem cells translational medicine.
[19] M. van Eijk,et al. GCase and LIMP2 Abnormalities in the Liver of Niemann Pick Type C Mice , 2021, International journal of molecular sciences.
[20] D. Galasko,et al. The Mutation Matters: CSF Profiles of GCase, Sphingolipids, α‐Synuclein in PDGBA , 2021, Movement disorders : official journal of the Movement Disorder Society.
[21] D. D. Di Monte,et al. GBA Mutations Influence the Release and Pathological Effects of Small Extracellular Vesicles from Fibroblasts of Patients with Parkinson’s Disease , 2021, International journal of molecular sciences.
[22] Jennifer C. Lee,et al. Membrane Interactions of α-Synuclein Probed by Neutrons and Photons. , 2021, Accounts of chemical research.
[23] Mark R. Marten,et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 , 2021, Autophagy.
[24] Frederik Ravnkilde Marlet,et al. The interplay between Glucocerebrosidase, α-synuclein and lipids in human models of Parkinson's disease. , 2020, Biophysical chemistry.
[25] M. Martínez-Vicente,et al. The Emerging Role of the Lysosome in Parkinson’s Disease , 2020, Cells.
[26] N. Mizushima,et al. Autophagy in Human Diseases. , 2020, The New England journal of medicine.
[27] M. Tittgemeyer,et al. GBA Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes , 2020, Movement disorders : official journal of the Movement Disorder Society.
[28] M. van Eijk,et al. Lyso-glycosphingolipids: presence and consequences , 2020, Essays in biochemistry.
[29] A. Desautels,et al. GBA variants in REM sleep behavior disorder , 2020, Neurology.
[30] P. Saftig,et al. Cholesterol Handling in Lysosomes and Beyond. , 2020, Trends in cell biology.
[31] A. Schapira,et al. Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons , 2020, Human molecular genetics.
[32] G. Knott,et al. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration , 2020, Proceedings of the National Academy of Sciences.
[33] A. Schapira,et al. Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation , 2020, Neurobiology of Disease.
[34] A. Singleton,et al. Genetics of Parkinson's disease: An introspection of its journey towards precision medicine , 2020, Neurobiology of Disease.
[35] D. Berg,et al. Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha‐Synuclein Profiles , 2020, Movement disorders : official journal of the Movement Disorder Society.
[36] E. Holzbaur,et al. Neuronal autophagy declines substantially with age and is rescued by overexpression of WIPI2 , 2019, Autophagy.
[37] Sonja W. Scholz,et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies , 2019, The Lancet Neurology.
[38] A. Ballabio,et al. Lysosomes as dynamic regulators of cell and organismal homeostasis , 2019, Nature Reviews Molecular Cell Biology.
[39] L. Casalis,et al. GM1 Ganglioside role in the interaction of Alpha-synuclein with lipid membranes: Morphology and structure. , 2019, Biophysical chemistry.
[40] M. Lipinski,et al. mTOR hyperactivity mediates lysosomal dysfunction in Gaucher's disease iPSC-neuronal cells , 2019, Disease Models & Mechanisms.
[41] S. Grinstein,et al. Lysosomal integral membrane protein-2 (LIMP-2/SCARB2) is involved in lysosomal cholesterol export , 2019, Nature Communications.
[42] M. Stamelou,et al. Autophagy dysfunction in peripheral blood mononuclear cells of Parkinson’s disease patients , 2019, Neuroscience Letters.
[43] A. Cuervo,et al. Proteome-wide analysis of chaperone-mediated autophagy targeting motifs , 2019, PLoS biology.
[44] Alan J. Thomas,et al. Dementia with Lewy bodies: an update and outlook , 2019, Molecular Neurodegeneration.
[45] M. Ivanova,et al. Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases , 2019, PloS one.
[46] G. Kroemer,et al. Biological Functions of Autophagy Genes: A Disease Perspective , 2019, Cell.
[47] Ottavio Arancio,et al. Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations , 2018, Autophagy.
[48] A. Mirelman,et al. Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene. , 2018, Parkinsonism & related disorders.
[49] Gennifer E. Merrihew,et al. Glucocerebrosidase deficiency promotes protein aggregation through dysregulation of extracellular vesicles , 2018, PLoS genetics.
[50] S. Linse,et al. Ganglioside lipids accelerate α-synuclein amyloid formation , 2018, Biochimica et biophysica acta. Proteins and proteomics.
[51] W. Wurst,et al. Exosomal secretion of α-synuclein as protective mechanism after upstream blockage of macroautophagy , 2018, Cell Death & Disease.
[52] J. Lanciego,et al. Glucocerebrosidase Mutations and Synucleinopathies. Potential Role of Sterylglucosides and Relevance of Studying Both GBA1 and GBA2 Genes , 2018, Front. Neuroanat..
[53] D. Krainc,et al. Acid ceramidase inhibition ameliorates &agr;-synuclein accumulation upon loss of GBA1 function , 2018, Human molecular genetics.
[54] Jennifer C. Lee,et al. Effects of phosphatidylcholine membrane fluidity on the conformation and aggregation of N-terminally acetylated α-synuclein , 2018, The Journal of Biological Chemistry.
[55] Joseph R. Mazzulli,et al. Is Parkinson's disease a lysosomal disorder? , 2018, Brain : a journal of neurology.
[56] N. Engedal,et al. The Long-lived Protein Degradation Assay: an Efficient Method for Quantitative Determination of the Autophagic Flux of Endogenous Proteins in Adherent Cell Lines. , 2018, Bio-protocol.
[57] V. Korolchuk,et al. mTORC1 and Nutrient Homeostasis: The Central Role of the Lysosome , 2018, International journal of molecular sciences.
[58] N. Hattori,et al. Loss of autophagy in dopaminergic neurons causes Lewy pathology and motor dysfunction in aged mice , 2018, Scientific Reports.
[59] T. Dawson,et al. α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism , 2018, Molecular Neurodegeneration.
[60] Elsje G. Otten,et al. mTORC1 as the main gateway to autophagy , 2017, Essays in biochemistry.
[61] M. Ehlers,et al. Lysosomal integral membrane protein-2 as a phospholipid receptor revealed by biophysical and cellular studies , 2017, Nature Communications.
[62] A. Schapira,et al. Insights into the structural biology of Gaucher disease , 2017, Experimental Neurology.
[63] R. Krüger,et al. The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p , 2017, Scientific Reports.
[64] S. Chandra,et al. Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease , 2017, The Journal of Neuroscience.
[65] M. Nalls,et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci , 2017, Nature Genetics.
[66] J. Kulisevsky,et al. N370S‐GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease , 2017, Movement disorders : official journal of the Movement Disorder Society.
[67] K. Marder,et al. Frequency of GBA Variants in Autopsy‐proven Multiple System Atrophy , 2017, Movement disorders clinical practice.
[68] L. Karageorgos,et al. Lipid composition of microdomains is altered in neuronopathic Gaucher disease sheep brain and spleen. , 2017, Molecular genetics and metabolism.
[69] R. Zoncu,et al. Lysosomal cholesterol activates mTORC1 via an SLC38A9–Niemann-Pick C1 signaling complex , 2017, Science.
[70] David M. Sabatini,et al. mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.
[71] M. Goedert,et al. The Synucleinopathies: Twenty Years On , 2017, Journal of Parkinson's disease.
[72] G. Schwarzmann,et al. Lipids regulate the hydrolysis of membrane bound glucosylceramide by lysosomal β-glucocerebrosidase , 2017, Journal of Lipid Research.
[73] J. Stirnemann,et al. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments , 2017, International journal of molecular sciences.
[74] D. James Surmeier,et al. Selective neuronal vulnerability in Parkinson disease , 2017, Nature Reviews Neuroscience.
[75] F. Platt,et al. The metabolism of glucocerebrosides - From 1965 to the present. , 2017, Molecular genetics and metabolism.
[76] R. Barker,et al. Dermal fibroblasts from patients with Parkinson's disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations. , 2017, F1000Research.
[77] J. Volkmann,et al. Parkinson disease , 2017, Nature Reviews Disease Primers.
[78] A. Schapira,et al. Glucocerebrosidase Mutations in Parkinson Disease. , 2017, Journal of Parkinson's Disease.
[79] D. Klionsky,et al. Autophagy wins the 2016 Nobel Prize in Physiology or Medicine: Breakthroughs in baker's yeast fuel advances in biomedical research , 2016, Proceedings of the National Academy of Sciences.
[80] L. Partridge,et al. A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin , 2016, The Journal of Neuroscience.
[81] Haiqun Lin,et al. Glucosylsphingosine is a key biomarker of Gaucher disease , 2016, American journal of hematology.
[82] Roberto Zoncu,et al. The Lysosome as a Regulatory Hub. , 2016, Annual review of cell and developmental biology.
[83] T. Outeiro,et al. Structure, function and toxicity of alpha‐synuclein: the Bermuda triangle in synucleinopathies , 2016, Journal of neurochemistry.
[84] C. Mariani,et al. Survival and dementia in GBA‐associated Parkinson's disease: The mutation matters , 2016, Annals of neurology.
[85] R. Barker,et al. Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's , 2016, Annals of neurology.
[86] A. Schapira,et al. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease , 2016, Human molecular genetics.
[87] L. Karageorgos,et al. Glycosphingolipid analysis in a naturally occurring ovine model of acute neuronopathic Gaucher disease , 2016, Neurobiology of Disease.
[88] D. Krainc,et al. Characterization of the complex formed by β-glucocerebrosidase and the lysosomal integral membrane protein type-2 , 2016, Proceedings of the National Academy of Sciences.
[89] S. Karlsson,et al. Glucosylated cholesterol in mammalian cells and tissues: formation and degradation by multiple cellular β-glucosidases[S] , 2016, Journal of Lipid Research.
[90] H. Christian,et al. ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons , 2016, Stem cell reports.
[91] P. Saftig,et al. Mannose 6‐phosphate‐independent Lysosomal Sorting of LIMP‐2 , 2015, Traffic.
[92] G. Halliday,et al. Lysosomal‐associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[93] Sarah C. Izen,et al. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons , 2015, Neurobiology of Disease.
[94] Xiao-Min Wang,et al. GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A , 2015, Autophagy.
[95] M. Lipinski,et al. Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells. , 2015, Human molecular genetics.
[96] C. Ortiz Mellet,et al. Pharmacological Chaperones and Coenzyme Q10 Treatment Improves Mutant β-Glucocerebrosidase Activity and Mitochondrial Function in Neuronopathic Forms of Gaucher Disease , 2015, Scientific Reports.
[97] B. Bembi,et al. Role of LIMP‐2 in the intracellular trafficking of β‐glucosidase in different human cellular models , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[98] A. Schapira. Glucocerebrosidase and Parkinson disease: Recent advances , 2015, Molecular and Cellular Neuroscience.
[99] M. Martínez-Vicente. Autophagy in neurodegenerative diseases: From pathogenic dysfunction to therapeutic modulation. , 2015, Seminars in cell & developmental biology.
[100] O. Isacson,et al. Progressive decline of glucocerebrosidase in aging and Parkinson's disease , 2015, Annals of Clinical and Translational Neurology.
[101] Frank Heinrich,et al. Structural Features of Membrane-bound Glucocerebrosidase and α-Synuclein Probed by Neutron Reflectometry and Fluorescence Spectroscopy* , 2014, The Journal of Biological Chemistry.
[102] J. Winkler,et al. Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment , 2014, Autophagy.
[103] G. Grabowski,et al. The LIMP-2/SCARB2 Binding Motif on Acid β-Glucosidase , 2014, The Journal of Biological Chemistry.
[104] E. Masliah,et al. Glucocerebrosidase depletion enhances cell-to-cell transmission of α-synuclein , 2014, Nature Communications.
[105] T. Sotnikova,et al. Exogenous α-Synuclein Decreases Raft Partitioning of Cav2.2 Channels Inducing Dopamine Release , 2014, The Journal of Neuroscience.
[106] Ying Sun,et al. Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. , 2014, Human molecular genetics.
[107] Chuong B. Do,et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.
[108] S. Gygi,et al. iPSC-derived neurons from GBA1-associated Parkinson’s disease patients show autophagic defects and impaired calcium homeostasis , 2014, Nature Communications.
[109] T. Foltynie,et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells , 2014, Brain : a journal of neurology.
[110] C. Ferrarese,et al. Reduced expression of the chaperone-mediated autophagy carrier hsc70 protein in lymphomonocytes of patients with Parkinson's disease , 2014, Brain Research.
[111] Y. Hirabayashi,et al. Cholesterol glucosylation is catalyzed by transglucosylation reaction of β-glucosidase 1. , 2013, Biochemical and biophysical research communications.
[112] M. Wittstock,et al. Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease Patients , 2013, PloS one.
[113] Peter Loppnau,et al. Structure of LIMP-2 provides functional insights with implications for SR-BI and CD36 , 2013, Nature.
[114] M. Xilouri,et al. LAMP2A as a therapeutic target in Parkinson disease , 2013, Autophagy.
[115] Jennifer C. Lee,et al. Saposin C protects glucocerebrosidase against α-synuclein inhibition. , 2013, Biochemistry.
[116] M. Flint Beal,et al. PGC-1α, mitochondrial dysfunction, and Huntington's disease. , 2013, Free radical biology & medicine.
[117] A. Leftin,et al. Solid-state ¹³C NMR reveals annealing of raft-like membranes containing cholesterol by the intrinsically disordered protein α-Synuclein. , 2013, Journal of molecular biology.
[118] A. Schapira,et al. Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Disease—Links to Parkinson’s Disease , 2013, Cell metabolism.
[119] D. Sillence. Glucosylceramide modulates endolysosomal pH in Gaucher disease. , 2013, Molecular genetics and metabolism.
[120] M. Nalls,et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. , 2013, JAMA neurology.
[121] A. Steven,et al. α-Synuclein Oligomers with Broken Helical Conformation Form Lipoprotein Nanoparticles* , 2013, The Journal of Biological Chemistry.
[122] M. Xilouri,et al. Loss of β-Glucocerebrosidase Activity Does Not Affect Alpha-Synuclein Levels or Lysosomal Function in Neuronal Cells , 2013, PloS one.
[123] A. Consiglio,et al. Interplay of LRRK2 with chaperone-mediated autophagy , 2013, Nature Neuroscience.
[124] M. Duchen,et al. Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage , 2013, Neurochemistry International.
[125] Jennifer C. Lee,et al. Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. , 2013, Molecular genetics and metabolism.
[126] T. Dawson,et al. Development and Characterization of a New Parkinson's Disease Model Resulting from Impaired Autophagy , 2012, The Journal of Neuroscience.
[127] S. Pang,et al. Genetic analysis of the LAMP-2 gene promoter in patients with sporadic Parkinson's disease , 2012, Neuroscience Letters.
[128] P. Saftig,et al. A Critical Histidine Residue Within LIMP‐2 Mediates pH Sensitive Binding to Its Ligand β‐Glucocerebrosidase , 2012, Traffic.
[129] A. Cuervo,et al. Dietary lipids and aging compromise chaperone-mediated autophagy by similar mechanisms , 2012, Autophagy.
[130] A. Schapira,et al. A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[131] P. Pollak,et al. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers , 2012, Neurology.
[132] H. Gerritsen,et al. Hyperacidification of Trans‐Golgi Network and Endo/Lysosomes in Melanocytes by Glucosylceramide‐Dependent V‐ATPase Activity , 2011, Traffic.
[133] M. V. van Breemen,et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. , 2011, Blood.
[134] J. Fantini,et al. The fusogenic tilted peptide (67-78) of α-synuclein is a cholesterol binding domain. , 2011, Biochimica et biophysica acta.
[135] R. Sidman,et al. CNS expression of glucocerebrosidase corrects α-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy , 2011, Proceedings of the National Academy of Sciences.
[136] Ying Sun,et al. Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies , 2011, Cell.
[137] Jennifer C. Lee,et al. α-Synuclein Interacts with Glucocerebrosidase Providing a Molecular Link between Parkinson and Gaucher Diseases* , 2011, The Journal of Biological Chemistry.
[138] Jifeng Li,et al. Altered expression of autophagic genes in the peripheral leukocytes of patients with sporadic Parkinson's disease , 2011, Brain Research.
[139] Chris Gardiner,et al. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission , 2011, Neurobiology of Disease.
[140] Shaoxiao Wang,et al. Defects in Very Long Chain Fatty Acid Synthesis Enhance Alpha-Synuclein Toxicity in a Yeast Model of Parkinson's Disease , 2011, PloS one.
[141] I. Ferrer,et al. Chaperone-mediated autophagy markers in Parkinson disease brains. , 2010, Archives of neurology.
[142] E. Rhoades,et al. Effects of curvature and composition on α-synuclein binding to lipid vesicles. , 2010, Biophysical journal.
[143] A. Steven,et al. Membrane Curvature Induction and Tubulation Are Common Features of Synucleins and Apolipoproteins* , 2010, The Journal of Biological Chemistry.
[144] A. Manning-Boğ,et al. Lysosomal Degradation of α-Synuclein in Vivo* , 2010, The Journal of Biological Chemistry.
[145] E. Masliah,et al. GFAP reactivity, apolipoprotein E redistribution and cholesterol reduction in human astrocytes treated with α-synuclein , 2010, Neuroscience Letters.
[146] E. Sidransky,et al. MUTATIONS IN GBA ARE ASSOCIATED WITH FAMILIAL PARKINSON DISEASE SUSCEPTIBILITY AND AGE AT ONSET , 2009, Neurology.
[147] Sonja W. Scholz,et al. Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.
[148] M. Nalls,et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. , 2009, The New England journal of medicine.
[149] A. Singleton,et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. , 2009, Brain : a journal of neurology.
[150] David Park,et al. Abberant α-Synuclein Confers Toxicity to Neurons in Part through Inhibition of Chaperone-Mediated Autophagy , 2009, PloS one.
[151] A. Brice,et al. Parkinson's disease: from monogenic forms to genetic susceptibility factors. , 2009, Human molecular genetics.
[152] A. Cuervo,et al. Entering the lysosome through a transient gate by chaperone-mediated autophagy , 2008, Autophagy.
[153] Kostas Vekrellis,et al. Wild Type α-Synuclein Is Degraded by Chaperone-mediated Autophagy and Macroautophagy in Neuronal Cells* , 2008, Journal of Biological Chemistry.
[154] M. Xilouri,et al. Alpha-synuclein degradation by autophagic pathways: A potential key to Parkinson’s Disease pathogenesis , 2008, Autophagy.
[155] A. Cuervo,et al. The Chaperone-Mediated Autophagy Receptor Organizes in Dynamic Protein Complexes at the Lysosomal Membrane , 2008, Molecular and Cellular Biology.
[156] Nir Giladi,et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset , 2008, Neurology.
[157] K. Uchida,et al. Aberrant molecular properties shared by familial Parkinson's disease-associated mutant UCH-L1 and carbonyl-modified UCH-L1. , 2008, Human molecular genetics.
[158] M. Langeveld,et al. Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. , 2008, Clinica chimica acta; international journal of clinical chemistry.
[159] P. Gómez-Puertas,et al. An evolutionary and structure‐based docking model for glucocerebrosidase–saposin C and glucocerebrosidase–substrate interactions—Relevance for Gaucher disease , 2008, Proteins.
[160] P. Saftig,et al. LIMP-2 Is a Receptor for Lysosomal Mannose-6-Phosphate-Independent Targeting of β-Glucocerebrosidase , 2007, Cell.
[161] Min Zhu,et al. GM1 Specifically Interacts with α-Synuclein and Inhibits Fibrillation† , 2007 .
[162] A. Cuervo,et al. Lysosome membrane lipid microdomains: novel regulators of chaperone‐mediated autophagy , 2006, The EMBO journal.
[163] Masaaki Komatsu,et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice , 2006, Nature.
[164] Hideyuki Okano,et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice , 2006, Nature.
[165] F. Kamp,et al. Binding of α-Synuclein Affects the Lipid Packing in Bilayers of Small Vesicles* , 2006, Journal of Biological Chemistry.
[166] Mario Maas,et al. Substrate reduction therapy of glycosphingolipid storage disorders , 2006, Journal of Inherited Metabolic Disease.
[167] F. Felicetti,et al. The N370S (Asn370-->Ser) mutation affects the capacity of glucosylceramidase to interact with anionic phospholipid-containing membranes and saposin C. , 2005, The Biochemical journal.
[168] Ad Bax,et al. Structure and Dynamics of Micelle-bound Human α-Synuclein* , 2005, Journal of Biological Chemistry.
[169] Peter T. Lansbury,et al. Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.
[170] M. Herkenham,et al. Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3 , 2003, Neurobiology of Disease.
[171] J. Sussman,et al. X‐ray structure of human acid‐β‐glucosidase, the defective enzyme in Gaucher disease , 2003, EMBO reports.
[172] R. Dwek,et al. Glucosylceramide modulates membrane traffic along the endocytic pathway Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200232-JLR200 , 2002, Journal of Lipid Research.
[173] Hansjürgen Bratzke,et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages) , 2002, Journal of Neurology.
[174] T. Linke,et al. Lysosomal Degradation on Vesicular Membrane Surfaces , 1998, The Journal of Biological Chemistry.
[175] M. L. Schmidt,et al. α-Synuclein in Lewy bodies , 1997, Nature.
[176] A. Cuervo,et al. A Receptor for the Selective Uptake and Degradation of Proteins by Lysosomes , 1996, Science.
[177] I. Goto,et al. The synthetic pathway for glucosylsphingosine in cultured fibroblasts. , 1994, Journal of biochemistry.
[178] C. Tanner. Epidemiology of Parkinson’s Disease , 1992, Neurologic Clinics.
[179] S. Freundlieb,et al. A selective pathway for degradation of cytosolic proteins by lysosomes. , 1990, Seminars in cell biology.
[180] J. Barranger,et al. Conditions affecting the activity of glucocerebrosidase purified from spleens of control subjects and patients with type 1 Gaucher disease. , 1990, Biochimica et biophysica acta.
[181] O. Reiner,et al. The human glucocerebrosidase gene and pseudogene: structure and evolution. , 1989, Genomics.
[182] R. Brady,et al. THE METABOLISM OF GLUCOCEREBROSIDES. I. PURIFICATION AND PROPERTIES OF A GLUCOCEREBROSIDE-CLEAVING ENZYME FROM SPLEEN TISSUE. , 1965, The Journal of biological chemistry.